ACXP News and Press, Acurx Pharmaceuticals Inc. From 03/16/23

2023-03-16 14:20:36 ET Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Conference Call March 16, 2023 08:00 ET Company Participants Robert Shawah - Co-Founder & Chief Financial Officer David Luci - President & Chief Executive Officer Conference Call...

2023-03-16 07:10:40 ET Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q4 GAAP EPS of -$0.28 beats by $0.15 . The Company ended the year, with cash totaling $9.1 million compared to $13.0 million as of December 31, 2021. For further details see: Acurx P...

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , March 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a cli...

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , March 6, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical...

--News Direct-- A New Gold Standard for C. diff Therapy Could be in the Offing; Next Data Release Expected in 2Q23 Clostridioides difficile/Clostridium difficile (C. diff) is a bacterial infection and is the most common cause of healthcare-associated diarrhea . C. ...

Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile New York, New York--(Newsfile Corp. - February 7, 2023) - Soulstring Media Group, Llc., a market research, aggrega...

(NewsDirect) By Faith Ashmore, Benzinga C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United States and it causes approximate...

Start Time: 08:30 End Time: 08:49 Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Conference Call November 14, 2022, 08:30 AM ET Company Participants David Luci - President and CEO Robert Shawah - Co-Founder and CFO Conference Call Participants ...

Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q3 GAAP EPS of -$0.32 misses by $0.04 . For further details see: Acurx Pharmaceuticals GAAP EPS of -$0.32 misses by $0.04

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Nov. 14, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical st...